What is Boundless Bio?
Boundless Bio is a pioneering biotechnology firm dedicated to the interrogation of extrachromosomal DNA (ecDNA) to address the unmet needs of patients suffering from oncogene-amplified cancers. By focusing on this novel area of cancer biology, the company aims to deliver transformative therapeutic interventions that target the fundamental drivers of tumor progression. Its market position is defined by a rigorous, data-driven approach to drug discovery, leveraging advanced genomic insights to develop precision medicines that offer superior efficacy compared to traditional oncology treatments.
How much funding has Boundless Bio raised?
Boundless Bio has raised a total of $251.4M across 3 funding rounds:
Series A
$46.4M
Series B
$105M
Series C
$100M
Series A (2019): $46.4M with participation from ARCH Venture Partners, Vertex Ventures, Alexandria Venture Investments, GT Healthcare Capital Partners, City Hill Ventures, and Boxer Capital
Series B (2021): $105M led by Fidelity Management & Research Company, PFM Health Sciences, Logos Capital, RA Capital Management, Surveyor Capital, Wellington Management, Redmile Group, and Nextech Invest
Series C (2023): $100M supported by RA Capital Management, Bayer, and Sectoral Asset Management
Key Investors in Boundless Bio
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Vertex Ventures
Vertex Ventures US is an early-stage venture capital firm that supports founders creating a smarter digital economy through B2B software, leveraging their experience as former founders and operators to provide operational insights and facilitate growth.
Alexandria Venture Investments
Alexandria Real Estate Equities, Inc. is a real estate investment trust that engages in the ownership, operation, and development of properties for the life sciences industry, providing critical infrastructure for biotechnology and pharmaceutical research entities.
What's next for Boundless Bio?
Following its recent strategic investment, Boundless Bio is poised to transition from early-stage research into more advanced clinical validation phases. The company's roadmap involves scaling its internal R&D capabilities and potentially entering into strategic partnerships to broaden the reach of its ecDNA-focused platform. As the firm continues to mature, the focus will likely shift toward optimizing its lead candidates for human trials, ensuring that its innovative therapeutic modalities can effectively address the complex challenges posed by oncogene-amplified malignancies in diverse patient populations.
See full Boundless Bio company page
